Lipum: Positive top-line results - Redeye

Redeye leaves a comment following Lipum’s announcement of positive top-line results from the phase I clinical trial with its lead candidate SOL-116. We are encouraged to learn that the candidate demonstrated a robust safety and tolerability profile, predictable pharmacokinetics and successful suppression of the target protein (BSSL).

Länk till analysen i sin helhet: https://www.redeye.se/research/1083695/lipum-positive-top-line-results?utm_source=finwire&utm_medium=RSS